(Adnkronos) - In questo numero:
Ipsos, ‘italiani promuovono Ssn, liste d’attesa prima criticità’
Ipofosfatasia, approvata da Aifa rimborsabilità di asfotase alfa
Al via ad Ancona il primo centro di Medicina di precisione – Heal Italia nelle Malattie rare, in occasione del primo convegno nazionale dei centri Heal Italia
Sla, concluso il progetto "Familiar-mente": formati venti assistenti familiari
Minelli (Lum), uso antibiotici distrugge tutti i batteri e danneggia il microbiota, importante intervenire con probiotici giusti
Fatturato record per Menarini nel 2024
Ipsos, ‘italiani promuovono Ssn, liste d’attesa prima criticità’
Ipofosfatasia, approvata da Aifa rimborsabilità di asfotase alfa
Al via ad Ancona il primo centro di Medicina di precisione – Heal Italia nelle Malattie rare, in occasione del primo convegno nazionale dei centri Heal Italia
Sla, concluso il progetto "Familiar-mente": formati venti assistenti familiari
Minelli (Lum), uso antibiotici distrugge tutti i batteri e danneggia il microbiota, importante intervenire con probiotici giusti
Fatturato record per Menarini nel 2024
Category
🗞
NewsTranscript
00:00In this issue, Ipsos, Italians promote national health service, waiting list, first
00:17criticism, hypophosphatasia, approved by AIFA, reimbursability of asphatase
00:23alpha. At the Via d'Ancona, the first precision medicine center in Italy
00:28in the rare diseases, on the occasion of the first national convention of the
00:31centers in Italy. And again, SLA has completed the project
00:36familiarly, formed 20 family assistants. Minelli, LUM, use of antibiotics,
00:42destroys all bacteria and damages the microbiota, it is important to intervene
00:47with the right probiotics. Record invoice for Minarini in 2024.
00:54Priorities and expectations of the Italians for a new national health system.
01:02This is the title of the Ipsos survey, presented in Rome on the occasion of the 7th edition
01:06of the Inventing for Life Health Summit, dedicated to the theme Investing for Life,
01:10Health and Accounts, organized by MSD Italy. Among the main data from the survey,
01:15health remains a priority for 74% of Italians, who believe to be the sectors
01:21on which the government should invest more and with more urgency.
01:24However, while still satisfied with the national health service,
01:28citizens point out criticism.
01:31In particular, the long waiting lists, which also the minister mentioned,
01:36as among other things, the focus of some solutions already in place,
01:40and the lack of medical and health staff.
01:46This, however, is not an obstacle to the improvement of some elements,
01:54including greater benevolence towards vaccines,
02:02greater awareness of the usefulness of preventive practices
02:08and an adherence to the digitization of medicine,
02:14which facilitates the interactions between doctor and patient.
02:19The key message of the meeting, according to MSD Italy,
02:22is linked to the opportunity to see in health a new glue,
02:25a new asset for the economic and social growth of Italy and Europe.
02:29I also think that it is well understood that health matters.
02:34It matters because the industrial sector of health, the pharmaceutical sector,
02:38is the sector that guides the growth of our country,
02:42it is the sector that guides the growth of Europe,
02:45and from a social point of view, it is an extraordinary opportunity,
02:50because in the face of demographic changes,
02:52in the face of new challenges, and also of policies and divisions that we must face,
02:59the opportunity to have a healthy population
03:03is a guarantee for a growth in prosperity.
03:06Francesco Saverio Mennini, Head of the Department of Pharmaceutical Programming,
03:10Devices and Health Professions of the Ministry of Health,
03:13explained what are the indicators to be taken into account
03:16when it comes to national health spending.
03:18Unfortunately, we always refer to this health spending ratio on the PIL,
03:22forgetting that it is the PIL that makes it the patron,
03:26because it is at the denominator, and by now everyone,
03:28even with the other economists,
03:30have widely demonstrated that this is not the indicator to be taken into account,
03:34also because a simulation we did a short time ago,
03:38only by putting the PIL of 2022 on the spending of 2024,
03:43we had exceeded 7% of the PIL spending ratio,
03:47so this means that these are two random measures
03:51that cannot be taken into account to see how much is being spent.
03:55Rather, we need to look at the pro-capita health spending ratio on pro-capita PIL,
03:59from which we see that Italy, in the last two years,
04:02has quickly approached the regression line,
04:05so we are approaching the level of spending that we can afford to spend.
04:11Still, if we make a comparison on pro-capita health spending,
04:15it is always said that we spend much less than France and Germany,
04:19in reality the differential on pro-capita health spending
04:23is lower than the differential between the PILs of these two countries.
04:29So we actually spend, as pro-capita health spending,
04:33if we go to read these data, even a little more than France and Germany,
04:37in relation to the PIL that we have and the PIL that they have.
04:47AIFA, the Italian pharmaceutical agency,
04:50has approved the reimbursement of Asfotase Alpha,
04:53a long-term replacement enzymatic therapy
04:56for patients affected by hypophosphatase in early childhood,
05:00a rare disease that in severe forms affects one person out of 300,000 in the general population.
05:06It was announced at AstraZeneca together with Alexion-AstraZeneca Rare Disease
05:11with a meeting with the press in Milan.
05:13Hypophosphatase or HPP in children
05:16involves premature loss of deciduous teeth,
05:19skeletal deformities, delay in walking and rachitism.
05:23These are children who have great difficulty in walking,
05:27great physical disproportions, obvious physical anomalies
05:32that, after the start of therapy,
05:35certainly have an improvement in physical performance,
05:39but the most striking part is at the radiographic level.
05:43A seriously disorganized bone,
05:46with a cartilaginous growth,
05:48with signs compatible with an important rachitism,
05:51I do not say that it is completely restored,
05:55but there is a sharp improvement
05:58both in bone mineralization and in the formation of new bone tissue.
06:04So bone alteration is treated
06:07determined by the absence of alkaline phosphatase.
06:10In adults, hypophosphatase manifests itself with fractures,
06:13pseudo-fractures, pain in the skeletal muscle,
06:16fatigue, dental anomalies, difficulty in walking.
06:20Italy did not have a great experience,
06:22simply because the drug was not refundable.
06:26So we could only give it to the most serious patients.
06:30There was a particular patient who was now lying in bed,
06:34with multiple femoral and vertebral fractures,
06:37assisted by the family.
06:39And after the pharmacological treatment,
06:41she came to my studio with a single stick,
06:43which for me was a miracle.
06:45The results observed with alpha-phosphatase
06:48are encouraging and improvements are noticeable
06:50in a few weeks of administration.
06:52The treatment is a beacon for patients.
06:55Today is a great day because we finally have the drug
06:58for children and young adults,
07:01which will change their lives in a total way.
07:04For more than 30 years, Alexion has been engaged
07:07in the research for the development of innovative therapies
07:10for people affected by rare diseases.
07:12For about 15 years we have started the development
07:15of a substitutional enzymatic therapy
07:19for alpha-phosphatase,
07:21for the treatment of hypophosphatase.
07:24We have taken risks in the field of research,
07:30for example, in hypophosphatase.
07:32And today we can be proud to say
07:35that this risk is worth taking,
07:39because we have been able to make it available
07:42to patients affected by hypophosphatase
07:46this important therapeutic innovation.
07:56Ancona brings them access to innovative diagnostic
07:58and therapeutic pathways for patients with rare diseases.
08:01In fact, the first precision medicine center
08:04Heal Italia was born here,
08:06dedicated to the development of precision medicine
08:08in rare diseases,
08:09carried out by the Department of Clinical and Molecular Sciences
08:11of the Università Politecnica delle Marche,
08:13directed by Professor Gianluca Moroncini.
08:15The activities of the new center officially started
08:17on February 28 and March 1,
08:19with the first precision medicine conference
08:21Heal Italia for rare diseases,
08:23of which Moroncini was responsible and scientific.
08:26Organized in the Montessori Hall of the Faculty of Medicine and Surgery
08:29of the Marchean Capoluogo,
08:30on the occasion of the World Day of Rare Diseases,
08:32which is usually celebrated on February 29,
08:34given that it is chosen for its low frequency,
08:37the conference was developed in two and a half days.
08:39But what is Heal Italia?
08:41And where does the need to give life to a center like this in Ancona come from?
08:44We asked Professor Moroncini.
08:46Heal Italia is an extensive partnership project
08:49dedicated to precision medicine,
08:51funded by the Ministry of the University of Research
08:54with funds from the PNRR.
08:56We are about 25 Italian universities,
08:59which are all practically connected
09:02around the University of Palermo,
09:04which is in fact the hub of this project
09:06and the real promoter of the project.
09:08Precision medicine is a new paradigm of medicine,
09:11so it starts from the unique model of prevention
09:15or angiotherapy that is good for all patients.
09:18Instead, it has a much more precise, structured project,
09:22so even within common diseases,
09:26rather than non-rare diseases,
09:27patients tend to be stratified,
09:29that is, to identify them for what are the characteristics,
09:33that is, the subgroups of diseases within the same group.
09:36This allows to optimize the prevention
09:39and diagnostic and therapeutic paths,
09:42not for all patients in the same way,
09:45but precisely optimized for subgroups.
09:48To celebrate the birth of this center,
09:51the top Italian precision medicine experts
09:53affiliated with this partnership
09:55were invited to Ancona.
09:57This conference is obviously open to students,
09:59colleagues, but also patients,
10:01their associations, their relatives,
10:03to make them understand a little
10:04about everything that is moving
10:05to improve research in the field of rare diseases.
10:08This new precision medicine center in Italy
10:10represents the fourth stage of the Illitalia Roadshow,
10:13an itinerant tour that the Illitalia Foundation
10:15launched in October 2024
10:17to create a permanent project in our country.
10:20These centers, in fact, have the ambition
10:22to create permanent infrastructures
10:25in the Italian research system
10:27and also, clearly, structures
10:30that then integrate heavily, fully
10:33with the national health service.
10:35So these precision medicine centers,
10:37this is the second one,
10:38in the first day, the PAC Cagliari,
10:40dedicated to oncology,
10:42other dedicated to other aspects
10:44of precision medicine will be born.
10:46Then they want to create their own territorial outposts
10:48and integrated with each other,
10:50which quickly transfer the results
10:53of laboratory research
10:55directly to the courtyards
10:57where the patients are.
10:59So it's about creating
11:01a permanent exchange system
11:03between laboratory and courtyards
11:05in such a way as to implement
11:07preventive, diagnostic and therapeutic
11:09paths in our country.
11:11But not only.
11:12After all, rare diseases,
11:13of which more than 6,000 pathologies
11:15are known so far
11:16and with less than 5 cases
11:17per 10,000 inhabitants,
11:18for a total of over 1 million cases in Italy
11:20and about 30 million in Europe,
11:22are extremely heterogeneous.
11:23And this complicates the diagnosis.
11:25The delay is much higher
11:26than in other diseases.
11:27And the cure is often
11:29devoid of specific therapies.
11:31The ambition to be able to be a reality
11:33that also occurs full-time in Europe
11:36is completely legitimate,
11:37as my center,
11:39like the other centers
11:40that participate in Italy,
11:42are already, in fact,
11:43in their respective areas,
11:44decent European reference centers.
11:46For example, the medical clinic I run
11:48is part of numerous networks
11:50in this sense.
11:51Network of connectivities,
11:53therefore dedicated to the treatment of connective tissue,
11:55network of scleroderma,
11:56network of vasculitis,
11:58network of inflammatory arthritis.
12:00So each of these centers
12:01already has its own consistency.
12:03But obviously,
12:04especially in the field of rare diseases,
12:06the sharing of data,
12:08of experiences,
12:10at the national level,
12:11is fundamental.
12:12So basically the FAR group
12:14is really the strength
12:16of the scientific work
12:17and the clinical work
12:18that we can all do together.
12:20The material of the convention
12:21and more information
12:22on the activities of the new center
12:24are available on the website
12:25www.ancona.centridimedicinediprecisione.it
12:36There are 20 disciples,
12:38family neo-assistants,
12:39who have completed
12:40the training course
12:42of the project
12:43FAMILIARMENTE IL VALORE DELLA CURA,
12:45born from the collaboration
12:47between the Italian Association
12:49of Amyotrophic Lateral Sclerosis
12:50and the Calabria Region.
12:52This morning,
12:53at the Cittadella Regionale,
12:54the ceremony
12:55of the certificates was held,
12:57the result of a 72-hour course
12:59of theoretical training
13:01with experts from the medical sector
13:03and practice with snipers
13:04in private public institutions.
13:06The collaboration between
13:07AISLA and the Calabria Region
13:09has proven to be successful
13:10for the social commitment,
13:11for the construction
13:12of a participatory welfare
13:13and community.
13:15As a regional association,
13:17activities are being carried out
13:21that are more and more
13:23in line with the needs
13:25of the citizens of Calabria
13:27when we hear about
13:29proximity welfare.
13:31This is what we have realized
13:33today in this project
13:35and a welfare that is
13:37closer to those families
13:39who have ASLA-affected patients.
13:41It is a huge result for us.
13:43With this course,
13:45we have finally reached
13:49another important goal,
13:51which is to guarantee
13:53our families
13:55and ASLA-affected people
13:57the possibility to access
13:59a list of people
14:01who are trained
14:03as family assistants
14:05specialized in ASLA care.
14:07So it is an absolutely
14:09important goal.
14:11The course wanted to highlight
14:13the importance not only of the patient,
14:15but also of the family members
14:17who live in a delicate condition.
14:19So the key word must be
14:21listening and welcoming,
14:23listening to the person with ASLA,
14:25getting in touch with the other
14:27and not proposing
14:29a pre-packaged package.
14:31I listen to what I have in front of me,
14:33I try to understand
14:35what the other person
14:37has understood
14:39about their path to the disease
14:41and I use my skills
14:43in the service of the other.
15:17It is very important, therefore,
15:19to choose the right products
15:21to use according to the case.
15:23Because, as the immunologist Mauro Minelli explains,
15:25a professor of dietetics and nutrition
15:27at the LUM University of Bari,
15:29even probiotics can affect
15:31the effectiveness of the same antibiotic therapy.
15:33Some probiotic therapies
15:35are associated with antibiotic therapies
15:37to try to neutralize
15:39the effect that antibiotics
15:41in general can have
15:43on the intestinal microbiota.
15:45Antibiotics are antibacterial
15:47and, being antibacterial,
15:49they do not have a selectivity
15:51in their action.
15:53They go there and practically kill
15:55the bacterial field
15:57they are facing.
15:59Therefore, in the definition
16:01of an antibiotic therapy,
16:03which, for heaven's sake,
16:05if it is needed, must be given,
16:07we must bear in mind
16:09that that antibiotic
16:11could also alter
16:13the antibiotic therapy
16:15into a probiotic therapy
16:17that is able to
16:19counteract the devastating effect
16:21that the antibiotic
16:23can generate,
16:25certainly on pathogenic bacteria,
16:27but also on healthy bacteria.
16:29Therefore, a continuous assumption
16:31of antibiotic therapy
16:33does not mean that it does not cause
16:35damage to the microbiota
16:37of the interested subject.
16:39I think, for example, of patients
16:41with colon verticolitis
16:43who, above all,
16:45were subjected to
16:47monthly therapy cycles
16:49with a specific antibiotic.
16:51Of course, the antibiotic was given
16:53to prevent the verticals
16:55from becoming infected,
16:57but we also killed
16:59a lot of good bacteria
17:01that belong to that intestine.
17:03Consequently, in these cases,
17:05I wonder if it was not the case
17:07to impose, rather than antibiotic therapies,
17:09probiotic therapies
17:11that are able to support
17:13the good bacterial component
17:15or, if there should ever be
17:17an antibacterial therapy,
17:19to associate
17:21an adequate probiotic therapy
17:23that is able to compensate
17:25the damage that the antibacterial does.
17:27However, an important thing
17:29about probiotic therapy
17:31is that the probiotic
17:33should not be able to transmit
17:35its antibiotic-resistant genes
17:37to pathogenic bacteria,
17:39otherwise we risk creating
17:41resistance of the bacteria
17:43to the antibiotic,
17:45which would then become
17:47absolutely inadequate
17:49compared to the therapies
17:51we propose to carry out.
17:53But not only.
17:55Let us remember that the altered microbiota
17:57is also able to interfere
17:59a lot on the therapies we do,
18:01in the sense that the bacteria
18:03of the microbiota can make
18:05some therapies worse.
18:07For example, mesalazine,
18:09which is a drug that is used
18:11to treat intestinal inflammatory diseases,
18:13is actually a pro-drug,
18:15that is, it is transported by a carrier
18:17to the seat in which it should function.
18:19Those who detach the vector
18:21from the drug are intestinal bacteria,
18:23so if in the intestine
18:25of that patient these bacteria
18:27should be missing, there is no
18:29detachment of the carrier
18:31from the pharmacologically active molecule
18:33and the drug will not work.
18:35The same goes for immunochemotherapies.
18:37It has been widely demonstrated
18:39that an abnormal bacterial population
18:41is able to interfere
18:43heavily
18:45on some immunochemotherapies,
18:47making those drugs
18:49ineffective,
18:51changing the intestinal microbiota
18:53of those patients through
18:55dedicated microbiota transplants.
18:57Those drugs that did not work before
18:59have magically started to work.
19:01This was published in 2015
19:03on Science, so on high-impact magazines,
19:05which have documented
19:07how the correct probiotics,
19:09or rather the correction
19:11of possible dysbiosis,
19:13can somehow even
19:15make effective therapies
19:17previously considered ineffective.
19:27An invoice that in 2024
19:29has exceeded 4.6 billion euros,
19:31with a growth of 5.2%
19:33compared to the previous year
19:35and an operating margin
19:37that will be between
19:39430 and 460 million euros.
19:41These are some of the numbers
19:43that Menarini Group,
19:45one of the Italian players
19:47with international projections
19:49in the pharmaceutical field,
19:51recorded in the last year.
19:53Yes, the company grew
19:55in 2024,
19:57with an invoice of
19:594.6 billion euros.
20:01Despite a very difficult
20:03global context,
20:05in some areas
20:07even challenging,
20:09we are very satisfied
20:11because our areas
20:13of greater competence
20:15have grown,
20:17such as the cardiology
20:19and respiratory area,
20:21but the oncological area
20:23has also grown,
20:25the company has been investing
20:27for a few years
20:29and has exceeded
20:31500 million euros
20:33and has developed
20:35especially in the United States.
20:37This makes the United States
20:39the second country
20:41dimensionally after Italy
20:43in the geographic
20:45panorama of the company,
20:47which includes 140 countries
20:49in the world.
20:51The pharmaceutical group presented
20:53in the Chamber of Commerce
20:55of Florence with a look
20:57at the future.
20:59We expect a 2025
21:01in line with the previous years,
21:03so a 2025 of growth
21:05where we are ready
21:07to respond to
21:09difficulties that
21:11in recent years
21:13present themselves
21:15at the level of some geography.
21:17The strong element
21:19of our company
21:21is the choice
21:23that continues
21:25to invest massively
21:27in research and development.
21:29I remember that the investment
21:31of 2024
21:33has reached 500 million euros,
21:35which means
21:3711% of our pharmaceutical
21:39investment,
21:41thanks to the will
21:43of the company
21:45to reinvest all
21:47its resources
21:49to strengthen
21:51and continue the growth path.
21:57This was our last news,
21:59to contact us you can write
22:01to salute-adnchronos.com
22:03Thank you for following us
22:05and see you in the next episode!
22:19www.adnchronos.com